Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma - Trial NCT00998010
Access comprehensive clinical trial information for NCT00998010 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jonsson Comprehensive Cancer Center and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
bortezomib + temozolomide+ radiation therapy
Interventional
drug
Sponsor & Location
Jonsson Comprehensive Cancer Center
Timeline & Enrollment
Phase 2
Oct 03, 2011
Apr 20, 2018
Primary Outcome
Overall Survival
Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes
 needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
 such as temozolomide, work in different ways to stop the growth of tumor cells, either by
 killing the cells or by stopping them from dividing. Radiation therapy uses high-energy
 x-rays to kill tumor cells. Giving bortezomib together with temozolomide and radiation
 therapy may kill more tumor cells and allow doctors to save the part of the body where the
 cancer started.
 
 PURPOSE: This phase II trial is studying the side effects and how well bortezomib works when
 given together with temozolomide and regional radiation therapy in treating patients with
 newly diagnosed glioblastoma multiforme or gliosarcoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT00998010
Non-Device Trial